References
- Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobovitz D. M., Kobin I. Primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia NIGRA by MPTP. Proceedings National Academy Science, USA, 1983; 80: 4546–4550
- Davis C. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Beichert C. M., Kopin I. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research 1979; 1: 249–254
- Donwiddle T. V., Worth T. Sedative and anticonvulsant effects of adenosine analogs in Mouse and Rat. Journal of Pharmacology & Experimental Therapeutics 1982; 220: 70–76
- Drury A. N., Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon mammalian heart. Journal of Physiology (London) 1929; 68: 213–237
- Eur A., Hefti F., Frick W. Acute administration of MPTP reduces dopamine and seratonine metabolism in the rat brain. European Journal of Pharmacology 1984; 101: 14–37
- Haulica J., Branisternau D., Ababei L. Topoliceanu, Preliminary data on the possible hynogenic role of adenosine. Journal of Neurochemistry 1973; 21: 1019–1021
- Kopin I. Z. Toxins and Parkinsons Disease: MPTP Parkinsonism in human and animals. Advances in Neurology 1986; 45: 137–144
- Radulovacki M., Virus M., Djorcic-Nedelson M., Green R. D. Adenosine analogs and sleep in rats. Journal of Pharmacological and Experimental Therapeutics 1984; 228: 268–274